This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Exactech, Inc. (Nasdaq: EXAC), which designs and manufactures bone and joint restoration products for hip, knee, shoulder and spine procedures, announced today that Exactech Chief Executive Officer Bill Petty, MD, will discuss the company’s financial highlights at Canaccord Genuity’s Musculoskeletal Conference in Chicago on March 19, 2013.
Exactech recently announced the company’s 2012 financial results that continue to surpass the overall growth of the company’s peers. Leading the way has been the Equinoxe® shoulder system, which for several years has been the fastest growing shoulder replacement system in the U.S.
Exactech growth also continues to be fueled by the introduction of new solutions for bone and joint reconstruction. Many of these products will be on display during the American Academy of Orthopedic Surgeons (AAOS) Annual Meeting at the company’s Booth # 4612, March 20 – 22, 2013, in Chicago. Additional details about Exactech and the products being showcased are available at
Learn more about the industry’s fastest growing shoulder system, Exactech’s Equinoxe® Platform Shoulder System as the company celebrates global “Equinoxe Day,” Wednesday, March 20. Just as the spring equinox on this date represents equal balance of day and night, Exactech’s Equinoxe shoulder system is designed to achieve balance in the shoulder joint. The Equinoxe Platform Shoulder System delivers innovative solutions to clinical challenges. The product family includes treatment options for both degenerative disease (primary and reverse total shoulder systems) as well as trauma (platform fracture stem and fracture plate). Throughout the AAOS exhibit time, design team surgeons and key clinicians will be on hand to share their experiences and provide product and instrument demonstrations and media interviews. Be among the first to see the latest additions to the Equinoxe product family:
Cage Glenoid, designed to offer several benefits including minimized operating room time 1 and enhanced fixation through interference fit of the plasma coated central cage.
A range of augmented glenoid options that can provide bone preserving solutions 2 for challenging glenoids, including the only augmented reverse baseplate options on the market.
Built on a design history spanning more than three decades, the Optetrak® and Optetrak Logic® total knee systems represent major advancements in knee implant design.
3 New enhancements to our knee solutions include:
Optetrak Logic CR Constrained insert provides additional anterior/posterior constraint in the absence of a well functioning PCL.
Optetrak Logic PS Constrained insert provides a conversion option from a posterior stabilized insert in surgery.
Exactech’s rotating bearing knee, Optetrak Logic RBK® (not available in the United States), and bone-preserving 4 Optetrak Logic PS are now available to select international markets.
Exactech Hip solutions address the continuum of hip arthroplasty. Recent additions to Exactech’s scope of hip solutions include:
Element tapered wedge stem featuring proportional neck geometries to accommodate a range of femoral anatomies.
Third generation porous material, InteGrip™, now available for our Crown Cup® acetabular system and augments
Large diameter heads and liners to address clinical challenges related to kinematics and wear.
® hip, knee and shoulder spacers are used in two stage revision procedures and provide orthopaedic surgeons with a unique and convenient way to treat this difficult problem. Latest additions to the product line include:
XL knee spacers and small shoulder spacers expand the options for joint sepsis treatment to a broader range of patient anatomies.
InterSpace continues to be the most widely studied spacer technology in the world. Information on more than 22 published journal articles demonstrating the clinical efficacy of InterSpace will be available at the booth.
Surgeons count on Exactech Spine for reproducible minimally invasive solutions, intuitive instrumentation for a simplified open approach, orthobiological material and services that allow them to improve patient outcomes and restore spine health. New to Exactech’s spine portfolio:
Slimmer, sleeker and more streamlined instrumentation for the Silverbolt® MIS Screw System.
Gibralt® Occipital Plate that enhances the Gibralt Spinal System, a comprehensive solution for posterior stabilization and fusion of the cervical and thoracic spine.
Exactech recognizes the growing importance of biologic solutions for orthopaedics. We are developing a position of leadership in biologics by designing and acquiring a broad range of innovative, clinically relevant biomaterials, delivery systems and surgical techniques. Come by the Exactech booth to learn about:
Optecure® bone matrix and the expanded flexibility of combining with bone marrow, in addition to autograft.
Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 35 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech, Inc. can be found at
http://www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at
An investment profile on Exactech may be found at
http://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up at
This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.